| PDF (7MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-339394
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.33939
Zusammenfassung
The capacity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to selectively induce cell death in malignant cells triggered numerous attempts for therapeutic exploitation. In clinical trials, however, TRAIL did not live up to the expectations, as tumors exhibit high rates of TRAIL resistance in vivo. Response to anti-cancer therapy is determined not only by cancer cell intrinsic ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik